NHE-1 inhibitors are experimentally and clinically validated pharmacological agents especially as potential cardioprotective therapies, agents against glaucoma and other disorders associated with ischemia and reperfusion, cell proliferative disorders and diabetes31,32. The gene discussed is SLC9A1; the disease is glaucoma.